ADVFN ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Premium Icon프리미엄 Help Menu
S&P 500
6,243.76
-0.40%
US Tech 100
22,216.40
-0.24%
다우존스 지수
44,023.29
-0.98%
Bitcoin
119,044.71
1.06%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Sarepta Therapeutics Inc New (SRPT) 시세

Sarepta Therapeutics Inc New

Sarepta Therapeutics Inc New (SRPT)

NASDAQ
18.21
-1.02
(-5.30%)
마감 16 7월 5:00AM
15분 지연 - 실시간으로 업그레이드
18.48
0.27
( 1.48% )
시간외 단일가: 5:53PM
15분 지연 - 실시간으로 업그레이드

Sarepta Therapeutics Inc New (SRPT) 주식 가격

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
18.48
( 1.48% )
매수가
18.30
매도가
18.48
거래량
9,018
0.00 일간 변동폭 0.00
16.88 52주 범위 153.30
market_cap
1.816B
전일 종가
18.21
개장가
-
최근 거래 시간
2
@
18.45
마지막 거래 시간
18:01:22
재정 규모
-
VWAP
-
평균 볼륨(3m)
5,703,447
발행 주식
98,277,032
배당수익률
-
주가수익률
7.61
주당순이익(EPS)
2.39
매출
1.9B
순이익
235.24M

Sarepta Therapeutics Inc New 정보

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for deve... Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.sarepta.com
본부
Wilmington, Delaware, USA
설립됨
-
Sarepta Therapeutics Inc New is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker SRPT. The last closing price for Sarepta Therapeutics was US$18.21. Over the last year, Sarepta Therapeutics shares have traded in a share price range of US$ 16.88 to US$ 153.30.

Sarepta Therapeutics currently has 98,277,032 shares in issue. The market capitalisation of Sarepta Therapeutics is US$1.79 billion. Sarepta Therapeutics has a price to earnings ratio (PE ratio) of 7.61.

Sarepta Therapeutics (SRPT) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

강세

순 프리미엄

104k

Calls / Puts

400.00%

매수 / 매도

150.00%

OTM / ITM

66.67%

Sweeps 비율

0.00%

SRPT 최신 뉴스

추가 뉴스

Form 8-K - Current report
Edgar (US Regulatory)
07 6월 2025
SRPT (-5.30%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.42-2.2222222222218.919.7917.95378992818.84170225CS
4-2.685-12.686038270721.16522.116.88569247118.57886877CS
12-43.17-70.024330900261.6564.816.88570344730.40514757CS
26-100.87-84.5161290323119.35120.0516.88368614142.75621503CS
52-133.63-87.8508973769152.11153.316.88230311960.9301978CS
156-65.24-77.926421404783.72173.116.88163971891.62188042CS
260-148.94-88.961892247167.42181.8316.88139397891.85220904CS

SRPT - Frequently Asked Questions (FAQ)

What is the current Sarepta Therapeutics share price?
The current share price of Sarepta Therapeutics is US$ 18.48
How many Sarepta Therapeutics shares are in issue?
Sarepta Therapeutics has 98,277,032 shares in issue
What is the market cap of Sarepta Therapeutics?
The market capitalisation of Sarepta Therapeutics is USD 1.79B
What is the 1 year trading range for Sarepta Therapeutics share price?
Sarepta Therapeutics has traded in the range of US$ 16.88 to US$ 153.30 during the past year
What is the PE ratio of Sarepta Therapeutics?
The price to earnings ratio of Sarepta Therapeutics is 7.61
What is the cash to sales ratio of Sarepta Therapeutics?
The cash to sales ratio of Sarepta Therapeutics is 0.94
What is the reporting currency for Sarepta Therapeutics?
Sarepta Therapeutics reports financial results in USD
What is the latest annual turnover for Sarepta Therapeutics?
The latest annual turnover of Sarepta Therapeutics is USD 1.9B
What is the latest annual profit for Sarepta Therapeutics?
The latest annual profit of Sarepta Therapeutics is USD 235.24M
What is the registered address of Sarepta Therapeutics?
The registered address for Sarepta Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Sarepta Therapeutics website address?
The website address for Sarepta Therapeutics is www.sarepta.com
Which industry sector does Sarepta Therapeutics operate in?
Sarepta Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
GTIGraphjet Technology
US$ 0.1426
(95.34%)
98.4M
NUWENewellis Inc
US$ 11.80
(71.14%)
1.47M
TNFATNF Pharmaceuticals Inc
US$ 0.1585
(49.25%)
14.55M
GAMEGameSquare Holdings Inc
US$ 2.10
(39.07%)
2.22M
DTSTData Storage Corporation
US$ 4.51
(33.43%)
667.38k
SLNHSoluna Holdings Inc
US$ 0.449
(-41.24%)
1.18M
CYCCCyclacel Pharmaceuticals Inc
US$ 7.94
(-35.60%)
85.92k
XELBXcel Brands Inc
US$ 1.16
(-28.40%)
278
PCLAPicoCELA Inc
US$ 0.64
(-20.99%)
98.32k
GANXGain Therapeutics Inc
US$ 1.41
(-17.06%)
1.53k
GTIGraphjet Technology
US$ 0.1426
(95.34%)
98.4M
IXHLIncannex Healthcare Ltd
US$ 0.4225
(24.26%)
17.06M
TNFATNF Pharmaceuticals Inc
US$ 0.1585
(49.25%)
14.55M
NCNANuCana PLC
US$ 0.0505
(0.60%)
2.57M
GAMEGameSquare Holdings Inc
US$ 2.10
(39.07%)
2.22M

SRPT Discussion

게시물 보기
johnhancoque johnhancoque 6 일 전
How many kids have died here?
👍️0
Zilla Zilla 3 주 전
17 makes even less sense
👍️0
Monroe1 Monroe1 3 주 전
uh oh legal eagles lurking
👍️0
tw0122 tw0122 4 주 전
Ride it back to $25
👍️0
Zilla Zilla 1 월 전
36.36 Doesn't make sense but it is what it is at the moment...
👍️0
theswordman theswordman 2 월 전
CBER
👍️0
north40000 north40000 2 월 전
SRPT trading at $35-$36/share.......what's great about that?   Sorry about market value loss. I sold our shares months ago at a profit/share that was far less than it used to be.
👍️0
Schmiggins Schmiggins 2 월 전
New CDER guy will actually be great for Sarepta.
In addition to allowing us to buy back shares even cheaper today!

He has bashed Elevidys and Sarepta in the past - the price and Mark's approval.

But now he needs to show that he's even-handed towards us. And next up or him and us will be the LMGD drugs which are clean cut as far as proof of concept and efficacy, so it'll be an easy win for him and us.
👍️0
axelvento axelvento 4 월 전
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies


https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-death-liver-failure/742765/


down
👍️0
Monksdream Monksdream 11 월 전
SRPT 10Q due AUGUST5
👍️0
Awl416 Awl416 1 년 전
Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains
👍️0
north40000 north40000 1 년 전
SRPT obtains an expanded approval by FDA for treatment of DMD. Share price is $174, +~ 56% on news.
👍️0
BottomBounce BottomBounce 2 년 전
$SRPT Total Debt (mrq) $1.38B back to $.50
👍️0
north40000 north40000 2 년 전
Readers might also check CPRX news release AH last Thursday, re FDA approval of a DMD drug for which CPRX has an exclusive license to market/sell in North America. CPRX plans introduction in early 2024.
👍️0
Schmiggins Schmiggins 2 년 전
Thanks. Like Barron's here, I speculated a while ago that if this trial succeeds as the company has long said it would - and we finally reach that happy $200 shore - I do think it may energize the XBI Biotech index ... which it looks like hasn't made any progress since 2015!!

It's like people think the science here is bogus, dead in the water. Well, it's not. And hopefully Sarepta is on the verge of proving that in the next few weeks.
👍️0
abew4me abew4me 2 년 전
Hi Joseph...and thanks for posting all of this information.

My curiosity of gene therapy doesn't really have anything to do with Sarepta other than to inquire if it breaks the double-strand in the DNA when it treats its patients?

The reason I ask that question is based on another company called BEAM. I don't want to go into detail here because it wouldn't be fair to the investors on this board. Please go to the BEAM board for more details.

Thanks

abe
👍️ 2
Joseph_K Joseph_K 2 년 전
abew4me (and unknown ghosts of the iHub Sarepta message board): Insurance funding for Elevidys has been a stock market issue for Sarepta. My (limited, but I think effective) due diligence in this has been in finding and keeping up with the Facebook page of Little Hercules Foundation. It has, I think, been assiduously following the issue, telling caretakers about both the insurers who have agreed to provide coverage (and any conditions thereon) and those denying coverage (with regard to which it tries to organize pressure campaigns). You'll have to review the entries yourself, but my (neither scientific nor well-organized) survey of them I felt showed that the considerable majority of insurers were providing coverage (per the rather restrictive current FDA label). If you look through those entries and conclude otherwise, please post your thoughts here. Once I did that bit of DD, I upped my investment.

You (abew) also asked about my DD on genomics. I don't remember what I posted. I do believe gene therapy will make many other cures obsolete. (I listen to a lot of science podcasts and read science books and articles some, too.) I think there was a Rett Syndrome genetic therapy in Phase 1, but all I recall doing was calculating how many years before it could possibly receive FDA approval.
👍️ 1
Joseph_K Joseph_K 2 년 전
Hi, Sarepta iHub ghost town. From Barron's:

The upside/downside trade-off for Sarepta Therapeutics [SPRT] is attractive going into the end of the year. We are coming up on results of what could be a confirmatory study of its gene-therapy drug for Duchenne muscular dystrophy. This could be a seminal moment for what has been a controversial stock, and provide a boost, albeit moderate, for the biotech space as a whole, especially
as the index is trending toward multiyear lows.
There appears to be two ways to win with Sarepta. One way is that the Phase 3 study shows an improvement for patients, even if very modest, but enough to illustrate a trend. This represents the base case or perhaps the most likely outcome, given the patient
population, but would also ensure that the gene therapy, which has already been conditionally approved by the Food and Drug
Administration (pending this trial), remains on the market. Best case, the trial demonstrates a statistically significant difference in the drug's favor versus the placebo, and Sarepta might address a larger market, including many patients who would otherwise not have access to the therapy. I believe that a positive trial would move the stock, now around $120, to or above $200 a share. If the drug fails to show even a modest benefit and investors remove gene therapy from models, a worst-case outcome could result in a stock price of around $60, depending on other assumptions. In the biotech sector, we are used to volatility.
👍️ 1
Schmiggins Schmiggins 2 년 전
Currently it's approved for only ages 4 and 5. CEO said there are 700 now in that age group in the US....The usual number of DMD kids born each year is 1 in 3,500. Check that with DMD organizations rather than what somebody plugged into some pretend "AI" toy. When approved for all ages you'd be talking 7,000 to 10,000. After they are all dosed (if that were to happen), then it reverts to maybe 350 a year. By that time it would be worldwide in the hands of Roche. I just saw a global number of 100,000. It is the most common rare disease.

Analysts and biotech journalists and scientists are the only ones who care about the drug and Sarepta and talk about it now that it's a success. its message boards are a barren desert where once it was an Amazonian rain forest.

I'm not sure how an individual investor can learn about the company's science at this point. Study the company's website for that. It's all there.

In a way, the fun (drama) is just about over. Just need the trial data in a few months to be good. The share price it seems to me will be under control of the big boys wanting to top off their positions before that data comes out. So it's a good time to do the same. After success in that trial is confirmed we'll be another Regeneron as far a stock goes. Possible much better. We should have as many diseases we can treat as it looks like Anavex will have someday.
👍️ 1
Joseph_K Joseph_K 2 년 전
I was pleased with yesterday's earnings and conference call. It also made me realize how much I know about blarcamesine! That is, I couldn't follow any of the discussion about Sarepta's research and trials in the call. But the expectation of broad insurance coverage and drug administration of the gene therapy before year's end has me optimistic enough to hold on to my now not-insubstantial Sarepta holdings through at least the first 2024 earnings report (assuming things appear to be proceeding as indicated yesterday).

Your calculation on Investor Village for administrations of the gene therapy will obviously have to slow down as, from what I gathered from the call, only 400 children per year are diagnosed with Duchenne. (Hmm, I just asked Google Bard, which replied, "According to the CDC, about 1 in 5,000 live male births in the United States are affected by Duchenne muscular dystrophy (DMD). This means that about 200 new cases of DMD are diagnosed in the US each year.") I guess, OTOH, it's a big world out there to expand into, though most of it will not be coughing up millions of dollars per child. (I hope there's some sort of charitable solution for them over time. What a horrible disease.)

Also, it was interesting, for a change, compared to Anavex, to hear a conference call with all these questions from analysts who work for companies I'd already heard of!
👍️0
Schmiggins Schmiggins 2 년 전
Hellooooo.....I hear an echo in here .....

Sarepta will be fine. I expect the strange people at the FDA to take another look at us in September/October and some are suggesting they will end the trial early (it will be finished in effect at that point anyway) due to unambiguous success seen ... and approve the drug for all ages - as they apparently told our CEO a few months ago would be "the label" upon any formal approval - which was expected to be early next year or late this year. But, as i say, some expect they take an October re-look at the trial and accept it's success and expand the label then and there. That will bring the stock to 200 more or less. That will unleash the dam and we can move on to other things, finally. Check out the Investor village board for more of my ranting and raving if you dare. Otherwise, maybe you can explore any other Sarepta boards - stocktwits? reddit? for me too .... and if you find one that's wiggling a bit more than this one (!) or IV, let me know...with links. (I'm pretty lame. I had a hard time finding this one again just now!) Thanks and all should be well now with Sarepta, finally.

Maybe there's someone here who can correct or expand on my info for newbie Mr. K's benefit. And to exercise your fingers a bit as well!
👍️ 1
Joseph_K Joseph_K 2 년 전
Hi, Schmiggins! Any thoughts on where Sarepta is heading? Your thoughts on staying invested or not? I bought in a week ago after the fall following the NDA approval, stupidly catching a falling knife, but so far retrospectively okay, at 111+ and 109+. I'm ahead for now, but ... (By the way, I have much less SRPT than AVXL. I've been in Anavex since mid-2021. I'm considerably underwater on Anavex, having doubled my holdings pre-market the morning after the CTAD conference in December 2022. AVXL shot up that morning then slid, slid, slid.)
👍️0
XWAVXALMIMAN XWAVXALMIMAN 2 년 전
Congrats to longs. Monday should be a good day. Anyone following Capricor - CAPR
CEO said CAPR drug helps cardiac election fraction and helps upper limb function in DMD. She says combination with Sarepta’s drug could be better than either alone. Maybe Sarepta should by Capricor?
👍️0
sorkin sorkin 3 년 전
Go SRPT , buyout AMLX
👍️0
TheFinalCD TheFinalCD 3 년 전
looking to get some $SRPT call options
👍️0
girlfriend girlfriend 3 년 전
Thankful I didn't sell all my shares.
👍️0
Atown62 Atown62 3 년 전
Good stuff
👍️0
girlfriend girlfriend 3 년 전
Indeed. Wish I had more shares but this market is freaky!
👍️0
Atown62 Atown62 3 년 전
Trend is UP…
👍️0
Atown62 Atown62 3 년 전
👍️0
girlfriend girlfriend 3 년 전
Thank you!
👍️0
Atown62 Atown62 3 년 전
https://musculardystrophynews.com/2022/03/21/mda-2022-dmd-boys-improved-walking-motor-function-3-years-after-srp-9001-gene-therapy/
👍️0
Atown62 Atown62 3 년 전
Cheers!
👍️0
girlfriend girlfriend 3 년 전
I have a core position in SRPT in an IRA. Been fun trading the high 60’s to 80ish channel over past year or so.

Good Luck about to board a plane back to the States!
👍️0
Atown62 Atown62 3 년 전
My large positions are this and $SOF.I @ 11.20
👍️0
girlfriend girlfriend 3 년 전
Yes it has. Especially considering biotech and therapeutics are out of favour for awhile.

👍️0
Atown62 Atown62 3 년 전
It’s been a decent trade
👍️0
girlfriend girlfriend 3 년 전
I was early buying these 68's but....added some 61's and 63's so actually am ahead right now. Nice comeback for SRPT today with the markets!
👍️0
girlfriend girlfriend 3 년 전
Bought a few more shares just now in low 68's.

Good Luck!
👍️0
Atown62 Atown62 4 년 전
You too
👍️0
girlfriend girlfriend 4 년 전
Have very few shares left….good luck to us.
👍️0
Atown62 Atown62 4 년 전
Lightened the load but Monday is a big news update regarding 9001-102 with JP
Morgan conference at 10:30AM


👍️0
Atown62 Atown62 4 년 전
This thing is just gonna chill at 80-85 until DI gets his hand outta his ass and updates 102 in January
👍️0
Atown62 Atown62 4 년 전
Same with $M

I’m anticipating a great 2022 especially with all the insider buying and anticipated news in January
👍️0
girlfriend girlfriend 4 년 전
I have been holding a smallish core position in an IRA and trading 100 size lots when appropriate. I usually let some go on good up days.

Otherwise.....be careful out there.

M...did let go of my entire position.
👍️0
Atown62 Atown62 4 년 전
I rebought my entire position and some with a now $79 average.
👍️0
Atown62 Atown62 4 년 전
Back in!
👍️0
Myth Myth 4 년 전
SRPT....

POS...
👍️0
Atown62 Atown62 4 년 전
I was waiting for 120.

And sold for a massive profit that was told to be “dead money”

It’s funny, cause atown is right again!

Srpt
👍️0
Myth Myth 4 년 전
I'm waiting for 120.00

the dilution news was GREAT !!
👍️0

최근 히스토리

NASDAQ
SRPT
Sarepta Therapeutics
Delayed Upgrade Clock
ADVFN
대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN Ltd - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지